Superior complete response rate and progression-free survival after autologous stem-cell transplantation (ASCT) incorporating velcade-thalidomide-dexamethasone (VTD)compared to thalidomide-dexametha-sone (TD) in newly diagnosed multiple myelona

MLA

Cavo, M., et al. Superior Complete Response Rate and Progression-Free Survival after Autologous Stem-Cell Transplantation (ASCT) Incorporating Velcade-Thalidomide-Dexamethasone (VTD)Compared to Thalidomide-Dexametha-Sone (TD) in Newly Diagnosed Multiple Myelona. Jan. 2009. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......4731..014b97119eceb18ad878b9e0fe83dd44&authtype=sso&custid=ns315887.

APA

Cavo, M., Pantani, L., Patriarca, F., Petrucci, M. T., Tacchetti, P., Galli, L., Di Raimondo, F., Crippa, C., Bringhen, S., Montefusco, V., Narni, F., Offidani, M., Spadano, T., Olivero, B., Pescosta, N., Caravita, T., Cellini, C., Ledda, A., Falcone, A., … Baccarani, M. (2009). Superior complete response rate and progression-free survival after autologous stem-cell transplantation (ASCT) incorporating velcade-thalidomide-dexamethasone (VTD)compared to thalidomide-dexametha-sone (TD) in newly diagnosed multiple myelona.

Chicago

Cavo, M, L Pantani, F Patriarca, M. T. Petrucci, P Tacchetti, L Galli, Francesco Di Raimondo, et al. 2009. “Superior Complete Response Rate and Progression-Free Survival after Autologous Stem-Cell Transplantation (ASCT) Incorporating Velcade-Thalidomide-Dexamethasone (VTD)Compared to Thalidomide-Dexametha-Sone (TD) in Newly Diagnosed Multiple Myelona,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......4731..014b97119eceb18ad878b9e0fe83dd44&authtype=sso&custid=ns315887.